RFL Rafael Holdings, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1713863 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.7%
TTM net income YoY-58.3%
TTM EPS YoY44.2%
Revenue 3-yr CAGR46.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,821.2%
Net margin-3,390.7%
FCF margin—
EBITDA margin-3,797.8%
Returns
ROE-36.9%
ROA-30.1%
ROIC (approx.)-61.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio2.35x
Interest coverage-100.29x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q4*2026-07-31 | 2026Q32026-04-30 | 2026Q22026-01-31 | 2026Q12025-10-31 | 2025Q4*2025-07-31 | 2025Q32025-04-30 | 2025Q22025-01-31 | 2025Q12024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $244,000 | $179,000 | $211,000 | $240,000 | $350,000 | $362,000 | $77,000 | $128,000 |
| Cost of revenue | — | — | — | — | — | — | $38,000 | $37,000 |
| Gross profit | — | — | — | — | — | — | $39,000 | $91,000 |
| R&D expense | $7.47M | $4.85M | $4.53M | $7.48M | $232,000 | $3.00M | $947,000 | $1.33M |
| SG&A expense | $2.44M | $2.14M | $2.27M | $2.84M | $58,000 | $3.17M | $2.59M | $2.52M |
| Operating income | -$9.73M | -$6.87M | -$6.66M | -$10.14M | -$12.76M | -$5.91M | -$6.64M | -$3.84M |
| Interest expense | $6,000 | $6,000 | $161,000 | $160,000 | $168,000 | $165,000 | $163,000 | $162,000 |
| Pretax income | -$9.00M | -$2.89M | -$6.28M | -$9.79M | -$12.23M | -$6.46M | -$5.31M | -$9.20M |
| Income tax | -$65,000 | $6,000 | $48,000 | $10,000 | -$174,000 | -$2.41M | $20,000 | $12,000 |
| Net income | -$9.18M | -$4.23M | -$6.42M | -$9.82M | -$290,000 | -$4.78M | -$4.64M | -$9.01M |
| EBITDA | -$9.68M | -$6.82M | -$6.60M | -$10.09M | -$12.71M | -$5.85M | -$6.55M | -$3.76M |
| EPS (basic) | — | -0.08 | -0.13 | -0.19 | — | -0.19 | -0.19 | -0.37 |
| EPS (diluted) | — | -0.08 | -0.13 | -0.19 | — | -0.19 | -0.19 | -0.37 |
| Weighted avg. shares (diluted) | — | 51.23M | 51.23M | 51.18M | — | 25.24M | 24.15M | 24.06M |
| Balance sheet | ||||||||
| Cash & equivalents | $22.10M | $30.50M | $37.78M | $45.54M | $52.77M | $52.77M | $48.32M | $8.16M |
| Short-term investments | — | — | — | — | — | — | — | $46.14M |
| Receivables | $444,000 | $294,000 | $295,000 | $413,000 | $627,000 | $414,000 | $200,000 | $201,000 |
| Inventory | $377,000 | $276,000 | $271,000 | $272,000 | $281,000 | $288,000 | — | — |
| Current assets | $25.82M | $34.86M | $42.45M | $48.32M | $56.71M | $42.44M | $65.83M | $70.48M |
| PP&E, net | $1.50M | $1.52M | $1.54M | $1.56M | $1.60M | $1.61M | $1.93M | $2.08M |
| Goodwill | $19.94M | $19.94M | $19.94M | $19.94M | $19.94M | $28.28M | — | $3.05M |
| Intangibles | $863,000 | $896,000 | $929,000 | $962,000 | $994,000 | $1.03M | $1.79M | $1.82M |
| Total assets | $83.06M | $91.99M | $99.31M | $105.38M | $114.11M | $108.10M | $83.04M | $87.83M |
| Current liabilities | $10.99M | $11.02M | $12.36M | $12.08M | $11.60M | $11.03M | $7.11M | $7.24M |
| Total liabilities | $11.09M | $11.19M | $16.06M | $16.20M | $15.74M | $23.58M | $10.48M | $10.45M |
| Shareholders' equity | $66.31M | $75.39M | $79.17M | $85.18M | $94.39M | $80.58M | $69.38M | $73.52M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.37M | -$7.28M | -$7.52M | -$6.81M | -$10.38M | -$3.19M | -$2.31M | -$3.04M |
| Capital expenditure | -$2,000 | $0 | — | — | -$1,000 | -$1,000 | $0 | $6,000 |
| Free cash flow | -$8.37M | -$7.28M | — | — | -$10.38M | -$3.19M | -$2.31M | -$3.05M |
| Investing cash flow | $3,000 | $6,000 | -$255,000 | -$430,000 | $163,000 | -$7.20M | $42.50M | $8.57M |
| Financing cash flow | -$26,000 | -$28,000 | -$32,000 | -$30,000 | $24.89M | $11,000 | -$27,000 | -$48,000 |
| Depreciation & amortization | $51,000 | $48,000 | $55,000 | $50,000 | $50,000 | $62,000 | $90,000 | $86,000 |
| Stock-based compensation | $231,000 | $172,000 | $387,000 | $598,000 | $909,000 | $353,000 | $502,000 | $359,000 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.